Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE: 603520)
Health Care · Pharmaceuticals · CN
CN¥8.72
-0.34% today · -20.8% 1Y
Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE: 603520) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $570.75M and employs 1,905 people.
Over the last twelve months the share price has lost 20.8%, trading between 7.89 and 14.37.
Tweenvest scores Zhejiang Starry Pharmaceutical Co.,Ltd. across four factors: quality 59/100, value 53/100, growth 56/100, dividend 49/100. Its strongest factor is quality.
603520 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $570.75M
- Revenue (TTM)
- $362.48M
- P/E
- 217.83
- EPS
- 0.04
- Dividend yield
- 3.44%
- Beta (5Y)
- 0.51
- 52-week high
- CN¥14.37
- 52-week low
- CN¥7.89
- Avg volume (3M)
- —
- Shares outstanding
- 438.41M
- Employees
- 1,905
- Next earnings
- —
About Zhejiang Starry Pharmaceutical Co.,Ltd.
Founded in 1997 and headquartered in Xianju, China, Zhejiang Starry Pharmaceutical Co.,Ltd. specializes in the research, production, and global distribution of X-CT non-ionic contrast agents and fluoroquinolone pharmaceuticals, along with their key intermediates. The company's extensive range of contrast agent products includes iohexol (and its hydrolysate and iodide derivatives), ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate. For fluoroquinolones, their offerings feature levofloxacin (and its hydrochloride salt), levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate.
- ISIN
- CNE1000026N8
- Founded
- 1997
- Listed since
- Mar 9, 2016
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Qianjiang Yongan Pharmaceutical Co., Ltd.SZSE: 002365 | $581.48M | CN¥13.47 | -0.07% |
| Zhejiang Yatai Pharmaceutical Co., Ltd.SZSE: 002370 | $580.00M | CN¥5.21 | +0.97% |
| Phathom Pharmaceuticals, Inc.NasdaqGS: PHAT | $575.87M | $7.25 | +4.77% |
| CorMedix Inc.NasdaqGM: CRMD | $575.23M | $7.38 | +0.82% |
| Gansu Longshenrongfa Pharmaceutical Industry CO.,LTDSZSE: 300534 | $567.01M | CN¥12.52 | -0.48% |
| Aclaris Therapeutics, Inc.NasdaqGS: ACRS | $563.77M | $3.83 | +1.06% |
| FDC LimitedBSE: 531599 | $555.31M | Rs330.10 | -1.62% |
| Xuanzhu Biopharmaceutical Co., Ltd.SEHK: 2575 | $552.76M | HK$8.38 | -4.56% |
Figures last refreshed Oct 11, 2026.